Who are AB-SA01's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Polymyxin e, Standard Dose Colistin, Coly Mycin M Injectable Product, CLS001 (Omiganan), Fexinidazole, Solosec.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ab-sa01.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

AB-SA01 — Competitive Intelligence Brief

AB-SA01 (AB-SA01) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimicrobial. Area: Infectious Diseases.

phase 2 Antimicrobial lipopolysaccharides Infectious Diseases Biologic Live · refreshed every 30 min

Target snapshot

AB-SA01 (AB-SA01) — Armata Pharmaceuticals, Inc.. AB-SA01 is a novel antimicrobial agent that targets and disrupts bacterial cell membranes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AB-SA01 TARGET	AB-SA01	Armata Pharmaceuticals, Inc.	phase 2	Antimicrobial	lipopolysaccharides
Polymyxin e	Polymyxin e	Mahmoud I Mostafa	marketed	Polymyxin antibiotic	Bacterial lipopolysaccharides and phospholipids
Standard Dose Colistin	Standard Dose Colistin	King Saud Medical City	marketed	Polymyxin antibiotic	Bacterial lipopolysaccharides and phospholipids
Coly Mycin M Injectable Product	Coly Mycin M Injectable Product	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	Polymyxin antibiotic	Bacterial lipopolysaccharides and phospholipids
CLS001 (Omiganan)	CLS001 (Omiganan)	Maruho Co., Ltd.	phase 3	Antimicrobial peptide	Bacterial cell membrane (lipopolysaccharides and lipoteichoic acids)
Fexinidazole	FEXINIDAZOLE	Sanofi	marketed	Nitroimidazole Antimicrobial [EPC]		2021-01-01
Solosec	SECNIDAZOLE	Evofem Inc	marketed	Nitroimidazole Antimicrobial [EPC]		2017-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimicrobial class)

Armata Pharmaceuticals, Inc. · 2 drugs in this class
Krishnadevaraya College of Dental Sciences & Hospital · 1 drug in this class
NovaBay Pharmaceuticals, Inc. · 1 drug in this class
Riyadh Colleges of Dentistry and Pharmacy · 1 drug in this class
SIFI SpA · 1 drug in this class
Savara Inc. · 1 drug in this class
Universitair Ziekenhuis Brussel · 1 drug in this class
University of Guarulhos · 1 drug in this class
VA Office of Research and Development · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AB-SA01 — Competitive Intelligence Brief. https://druglandscape.com/ci/ab-sa01. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab